Medikamentös bedingte Blutungskomplikationen in der internistischen Intensivmedizin

• LITERATUR

• 1 Bechthold H, Andrassy K, Jähnchen E, Koderisch J, Koderisch H, Weilemann L. S, Sonntag H. G, Ritz E. Evidence for impaired hepatic vitamin K₁ metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb. Haemostas. 51: 358-361 1984;
• 2 Brown C. H, Bradshaw H, Natelson E. A, Alfrey C. P, Williams T. W. Defective platelet function following the administration of penicillin compounds. Blood 47: 949-956 1976;
• 3 Brown C. H, Natelson E. A, Bradshaw M. W, Alfrey C. P, Williams T. W. Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob. Agents Chemother. 07: 652-657 1963;
• 4 Brown C. H, Natelson E. A, Bradshaw M. W, Williams T. W, Alfrey C. P. The hemostatic defect produced by carbenicillin. New Engl. J. Med. 291: 265-270 1964;
• 5 Cazenave J-P, Reimers H-J, Senyi A. F, Hirsh J, Packham M. A, Mustard J. F. Effects of penicillin G and cephalotin on platelet function in vivo. Proc. Soc. Exp. Biol. Med. 152: 141-144 1976;
• 6 Chastre J, Cornud F, Bouchama A, Vian F, Benacerraf R, Gibert C. Thrombosis as a complication of pulmonary-artery catheterization via the internal jugular vein. Prospective evaluation by phlebography. New Engl. J. Med. 306: 278-281 1982;
• 7 Clancy C. M, Glew R. H. Hypoprothrombinaemia and bleeding associated with cephamandole. Lancet I: 250 1983;
• 8 Clive D. M, Stoff J. S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. New Engl. J. Med. 310: 563-572 1984;
• 9 Colman R. W, Robboy S. J, Minna J. D. Disseminated intravascular coagulation (DIC): An approach. Amer. J. Med. 52: 679-689 1972;
• 10 Copelan E. A, Kusumi R. K, Miller L, Fass R. J. A comparison of the effect of mezlozillin and carbenicillin on hemostasis in volunteers. J. Antimicr. Chemotherapy. 11 (Suppl. C): 43 1983;
• 11 Deykin D. Hemorrhagic complications of drugs. In: Colman R. W, Hirsh J, Marder V. J, Salzman E. W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott, Philadelphia, Toronto: 1982: 602-611.
• 12 Deykin D. Uremic bleeding. Kidney Intern. 24: 698-705 1983;
• 13 Dijkmans B. A. C, van der Meer J. W. M, Boekhout-Mussert M. J, Zaalde-Jong M, Mattie H. Prolonged bleeding time during azlozillin therapy. J. Antimicrob. Chemother. 06: 554-556 1980;
• 14 Duckert F, Marbet G. A. Therapeutische Fibrinolyse (Thrombolyse). In: Koller F, Duckert F. Thrombose und Embolie. Schattauer, Stuttgart; New York: 1983: 423-448.
• 15 Editorial: Antimicrobials and Haemostasis. Lancet I: 510-511 1983;
• 16 European Cooperative Study Group of Streptokinase Treatment in Acute Myocardial Infarction: Streptokinase in acute myocardial infarction. New Engl. J. Med. 301: 797-802 1979;
• 17 Fainstein V, Bodey G, McCredie K, Keating M, Estey E, Bolivar R, Elting L. Coagulation abnormalities induced by beta lactam antibiotics in cancer patients. J. Infect. Dis. 148: 745-750 1983;
• 18 Feliciano D. V, Mattox K. L, Graham J. M, Beall A. C, Jordan G. L. Major Complications of percutaneous subclavian vein catheters. Amer. J. Surg. 138: 869-874 1979;
• 19 Foote G. A, Schabel S. I, Hodges M. Pulmonary complications of the flow-directed balloon-tipped catheter. New Engl. J. Med. 290: 927-931 1974;
• 20 Gardner F. H, Bessman J. D. Thrombocytopenia due to defective platelet production. Clin. Haematol. 12: 23-38 1983;
• 21 Gardner R. M, Schwartz R, Wong H. C, Burke J. P. Percutaneous indwelling radialartery catheters for monitoring cardiovascular function. Prospective study of the risk of thrombosis and infection. New Engl. J. Med. 290: 1227-1231 1974;
• 22 Gentry L. O, Jemsek J. G, Natelson E. A. Effects of sodium piperacillin on platelet function in normal volunteers. Antimicrob. Agents Chemother. 19: 532-533 1981;
• 23 Goldberg S, Greenspon A. J, Urban P. L. et al. Reperfusion arrhythmia: a marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarction. Amer. Heart J. 105: 26-32 1983;
• 24 Goldenheim P. D, Kazemi H. Cardiopulmonary monitoring of critically ill patients (two parts). New Engl. J. Med. 311. 717-720: 776-780 1984;
• 25 Haburchak D. R, Head D. R, Everett E. D. Postoperative hemorrhage associated with carbenicillin administration. Amer. J. Surg. 134: 630-634 1977;
• 26 Hooper C. A, Haney B. B, Stone H. H. Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole. Lancet I: 39-40 1980;
• 27 Hory B, Saint-Hillier Y, Perol J. C. Prostacyclin as the sole antithrombotic agent for acute renal failure hemodialysis. Nephron 33: 71 1983;
• 28 King D. J, Kelton J. G. Heparin-associated thrombocytopenia. Ann. Int. Med. 100: 535-540 1984;
• 29 Kirchhof B, van de Loo J. Fibrinolytische Behandlung bei akutem Herzinfarkt. Hämostaseologie 01: 33-39 1981;
• 30 Laffel G. L, Braunwald E. Thrombolytic therapy: A new strategy for the treatment of acute myocardial infarction (two parts) New Engl. J. Med. 311 710-717: 770-776 1984;
• 31 Lechner K, Niessner H, Thaler E. Coagulation abnormalities in liver disease. Sem. Thromb. Hemostas. 04: 50-56 1977;
• 32 Lind S. E. Prolonged bleeding time. Amer. J. Med. 77: 305-312 1984;
• 33 Lipsky J. N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamine acid: possible mechanism for antibiotic-associated hypoprothrombinemia. Lancet II: 192-193 1983;
• 34 Mathey D. G, Schofer J, Kuck K-U, Bell U, Klöppel G. Transmural, haemorrhagic myocardial infarction after intracoronary streptokinase: clinical, angiographic and necropsy findings. Brit. Heart J. 48: 546-551 1982;
• 35 Matthews M. W, Kuhn J. L, Smalling R. W. et al. Incidence of bleeding complications associated with intracoronary streptokinase therapy for acute myocardial infarction. Circulation 68 Suppl. 3: III-292 abstr. 1983;
• 36 McClure P. D, Casserly J. G, Monsier C, Crozier C. Carbenicillin-induced bleeding disorder. Lancet II: 1307-1308 1970;
• 37 McMillan R. Immune thrombocytopenia. Clin. Haematol. 12: 69-88 1983;
• 38 Natelson E. A, Brown C. H, Bradshaw M. W, Alfrey C. P, Williams T. W. Influence of cephalosporin antibiotics on blood coagulation and platelet function. Antimicrob. Agents Chemother 09: 91-93 1976;
• 39 Natelson E. A, Siebert W. T, Williams T. W, Bradshaw M. W. Combined effects of ticarcillin and cefazolin on blood coagulation and platelet function. Am. J. Med. Sei. 278: 207-227 1979;
• 40 Neu H. C. The new beta-lactamase stable cephalosporins. Ann. Int. Med. 97: 408-419 1982;
• 41 Neu H. C. Adverse effects of new cephalosporins. Ann. Int. Med. 98: 415-416 1983;
• 42 Neuhaus K. L, Tebbe J. U, Sauer G, Köstering H, Kreuzer K. High dose intravenous streptokinase infusion in acute myocardial infarction. Eur. Heart J. 02 (Suppl. A): 144 abstr. 1981;
• 43 Pape L. A, Haffajee C. I, Markis J. E, Ockene I. S, Paraskos J. A, Dalen J. E, Alpert J. S. Fetal pulmonary hemorrhage after use of the flow-directed balloon-tipped catheter. Ann. Int. Med. 90: 344-347 1979;
• 44 Pinnick R. V, Wiegmann T. B, Diedrich D. A. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. New. Engl. J. Med. 308: 258-261 1983;
• 45 Rao A. K, Walsh P. N. Acquired qualitative platelet disorders. Clin. Haematol. 12: 201-238 1983;
• 46 Rosenberg R. D. Heparin-AntithrombinSystem. In: Colman R. W, Hirsh J, Marder V. J, Salzman E. W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott, Philadelphia Toronto: 1982: 962-985.
• 47 Schröder, Biamino R. G, Enz-Rüdiger V. L. et al. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation. 67: 536-548 1983;
• 48 Sharma G. V. R. K, Cella G, Parisi A. F, Sasahara A. A. Thrombolytic therapy. New Engl. J. Med. 306: 1268-1276 1982;
• 49 Shattil S. J, Bennett J. S, McDonough M, Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J. Clin. Invest. 65: 329-337 1980;
• 50 Six P, Marbet G. A, Walter M, Nyman D, Duckert F, Madar G, da Silva A, Widmer L. K, Ritz R. Nebenwirkungen bei verschiedenen Thrombolysemethoden. In: Niehaus K, Duckert F. (Eds.): Blutgerinnung und Antikoagulation. Schattauer, Stuttgart; New York: 1976: 111.
• 51 Somani P, Smith M. R, Gohara A, Kapila K. The effects of mezlocillin, ticarcillin and placebo on blood coagulation and bleeding time in normal volunteers. Antimicrob. Agents Chemother. 19: 532-540 1981;
• 52 Spann J. F, Sherry S, Carabello B. A. et al. Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction: acute and follow-up studies. Amer. J. Cardiol. 53: 655-661 1984;
• 53 Swartz R. D. Hemorrhage during highrisk hemodialysis using controlled heparinization. Nephron. 28: 65-69 1981;
• 54 Swartz R. D, Port F. K. Preventing hemorrhage in high-risk hemodialysis: Regional versus low-dose heparin. Kidney Intern. 16: 513-518 1979;
• 55 van de Werf F, Ludbrook P. A, Bergmann S. R, Tiefenbrunn A. J, Fox K. A, de Geest H, Verstraete M, Collen D, Sobel B. E. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. New Engl. J. Med. 310: 609-613 1984;
• 56 Verstraete M, Vermylen J. Thrombosis. Pergamon Press; 1984
• 57 Weinstein J. Treatment of myocardial infarction with intracoronary streptokinase: efficacy and safety data from 209 United States cases in the Hoechst-Roussel registry. Amer. Heart J. 104: 894-898 1982;
• 58 Weitekamp M. R, Aber R. C. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 249: 69-71 1983;
• 59 World J. S, Buening M. K, Hanasono G. K. Latamoxef-associated hypoprothrombinaemia. Lancet II: 408 1983;
• 60 Zusman R. M, Rubin R. H, Cato A. E, Cocchetto D. M, Crow J. W, Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. New Engl. J. Med. 304: 934-939 1981;